Kuick Research is an Indian company providing detailed reports on data and accurate in-depth analysis. The company’s vision is to become among the best-known knowledge partners in market research for companies worldwide.
Recently the company has released a new report, “India Biosimilar Market Analysis“.
Launching biosimilar products in India also provides firms with an advantage to develop their post-marketing safety and efficacy data. This is specifically significant for biosimilar products as even minor changes in manufacturing processes may lead to serious health issues. Nevertheless, the biosimilar market is still nascent to gauge which of these differences is significant in determining the safety and efficacy impacts.
In 2011, there were about 15 epoetin, 8 G-CSF and 4 insulin biosimilars available in the Indian market. The acceptability of biosimilars is higher in the domestic market. Biosimilar substitution is automatic and can take place as soon as a biosimilar is launched. But as discussed several times before, none of the Indian products are developed under globally accepted biosimilar guidelines, yet.
If you want to buy the report, you can check the table of contents and rates from here: